Exelixis today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumours. The results from the first part of this phase 1 trial will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held in Copenhagen on 7-11 October 2016.
The results of the cabozantinib/nivolumab combination are promising, with an objective response rate of 43% among the 23 patients who were evaluable for response. Four of six patients (67%) with urothelial cancer (only one of these patients had renal cell carcinoma) achieved a response. Part II of the phase 1 trial examining the use of the triplet combination of cabozantinib, nivolumab, and ipilimumab is ongoing.
The researchers said, “These promising early stage clinical findings support further investigation of cabozantinib in combination with nivolumab in a number of genitourinary tumors.”